The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders Meeting Abstract
| Authors: | Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; Neylon, E.; Hamelers, R.; Zelenetz, A.; Myers, T. J.; Boral, A. L.; O'Connor, O. A. |
| Abstract Title: | The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders |
| Meeting Title: | 48th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 108 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2006 Dec 9-12 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2006-11-01 |
| Start Page: | 781A |
| Language: | English |
| ACCESSION: | WOS:000242440003548 |
| PROVIDER: | wos |
| PUBMED: | 17139767 |
| DOI: | 10.1182/blood.V108.11.2759.2759 |
| Notes: | --- - Meeting Abstract: 2759 - 48th Annual Meeting of the American-Society-of-Hematology - DEC 09-12, 2006 - Orlando, FL - Part 1 - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
